ALS' (ASX:ALQ) investors will be pleased with their stellar 143% return over the last five years
So let's assess the underlying fundamentals over the last 5 years and see if they've moved in lock-step with shareholder returns.
AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.
There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.
Over half a decade, ALS managed to grow its earnings per share at 26% a year. The EPS growth is more impressive than the yearly share price gain of 16% over the same period. Therefore, it seems the market has become relatively pessimistic about the company.
You can see how EPS has changed over time in the image below (click on the chart to see the exact values).
We like that insiders have been buying shares in the last twelve months. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. This free interactive report on ALS' earnings, revenue and cash flow is a great place to start, if you want to investigate the stock further.
What About Dividends?
As well as measuring the share price return, investors should also consider the total shareholder return (TSR). Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. Arguably, the TSR gives a more comprehensive picture of the return generated by a stock. In the case of ALS, it has a TSR of 143% for the last 5 years. That exceeds its share price return that we previously mentioned. And there's no prize for guessing that the dividend payments largely explain the divergence!
A Different Perspective
We're pleased to report that ALS shareholders have received a total shareholder return of 23% over one year. Of course, that includes the dividend. That gain is better than the annual TSR over five years, which is 19%. Therefore it seems like sentiment around the company has been positive lately. In the best case scenario, this may hint at some real business momentum, implying that now could be a great time to delve deeper. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. For instance, we've identified 1 warning sign for ALS that you should be aware of.
If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: most of them are flying under the radar).
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Australian exchanges.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
3 ASX Penny Stocks With Market Caps Under A$2B To Consider
As the Australian market braces for fresh CPI data from the ABS, investors are keeping a close watch on potential economic shifts that could influence trading strategies. Amidst these developments, penny stocks—despite their somewhat outdated moniker—remain an intriguing investment area due to their potential for discovering undervalued opportunities. In this article, we explore three ASX-listed penny stocks that exhibit strong financial foundations and promise hidden value for discerning investors. Top 10 Penny Stocks In Australia Name Share Price Market Cap Financial Health Rating Alfabs Australia (ASX:AAL) A$0.40 A$114.64M ★★★★☆☆ EZZ Life Science Holdings (ASX:EZZ) A$2.18 A$102.84M ★★★★★★ GTN (ASX:GTN) A$0.575 A$109.63M ★★★★★★ IVE Group (ASX:IGL) A$2.94 A$453.29M ★★★★★☆ West African Resources (ASX:WAF) A$2.30 A$2.62B ★★★★★★ Southern Cross Electrical Engineering (ASX:SXE) A$1.76 A$465.36M ★★★★★★ Regal Partners (ASX:RPL) A$3.01 A$1.01B ★★★★★★ Sugar Terminals (NSX:SUG) A$0.99 A$360M ★★★★★★ Bisalloy Steel Group (ASX:BIS) A$4.01 A$190.27M ★★★★★★ CTI Logistics (ASX:CLX) A$1.84 A$148.2M ★★★★☆☆ Click here to see the full list of 463 stocks from our ASX Penny Stocks screener. Let's dive into some prime choices out of the screener. BKI Investment Simply Wall St Financial Health Rating: ★★★★★☆ Overview: BKI Investment Company Limited is a publicly owned investment manager with a market cap of A$1.47 billion. Operations: The company generates revenue of A$69.33 million from the securities industry. Market Cap: A$1.47B BKI Investment Company Limited, with a market cap of A$1.47 billion, reported revenue of A$69.33 million for FY2025, showing slight growth from the previous year. Despite being debt-free for five years and maintaining high-quality earnings, BKI's net income declined to A$61.86 million from A$64.39 million last year, with a lower net profit margin of 89.2%. The company's dividend yield is 4.34%, but it's not well covered by earnings or free cash flows, raising sustainability concerns despite experienced board oversight and stable weekly volatility at 1%. Jump into the full analysis health report here for a deeper understanding of BKI Investment. Evaluate BKI Investment's historical performance by accessing our past performance report. Helloworld Travel Simply Wall St Financial Health Rating: ★★★★★★ Overview: Helloworld Travel Limited is a travel distribution company operating in Australia, New Zealand, and internationally with a market cap of A$270.47 million. Operations: The company's revenue is primarily generated from Travel Operations in Australia (A$153.71 million), New Zealand (A$36.06 million), and the Rest of World (A$3.72 million), along with contributions from Transport, Logistics, and Warehousing (A$15.20 million). Market Cap: A$270.47M Helloworld Travel Limited, with a market cap of A$270.47 million, has been involved in merger discussions with Webjet Group and BGH Capital, potentially leading to a strategic consolidation. Despite recent negative earnings growth of -22.9%, Helloworld has maintained profitability over the past five years and is debt-free, offering financial stability. The company's short-term assets exceed its liabilities, but its 6.65% dividend isn't well covered by free cash flows, posing sustainability questions. Trading at a price-to-earnings ratio of 10.4x below the Australian market average suggests it might offer value compared to peers despite current challenges in earnings growth and profit margins declining from last year's levels. Click to explore a detailed breakdown of our findings in Helloworld Travel's financial health report. Gain insights into Helloworld Travel's future direction by reviewing our growth report. PharmX Technologies Simply Wall St Financial Health Rating: ★★★★★★ Overview: PharmX Technologies Limited is a technology and software development company operating in Australia with a market cap of A$71.82 million. Operations: PharmX Technologies generates revenue primarily from its Health Services segment, which accounted for A$7.07 million. Market Cap: A$71.82M PharmX Technologies, with a market cap of A$71.82 million, primarily generates revenue from its Health Services segment (A$7.07 million). The company is debt-free, eliminating interest payment concerns and demonstrating financial stability with short-term assets (A$5.7M) surpassing liabilities (A$1.1M). Despite negative earnings growth (-94.7%) over the past year and low return on equity (0.09%), PharmX has avoided shareholder dilution recently and maintains an experienced management team with a 2.8-year average tenure. However, profit margins have declined to 0.2% from last year's 4.2%, indicating challenges in maintaining profitability amidst industry pressures. Take a closer look at PharmX Technologies' potential here in our financial health report. Assess PharmX Technologies' previous results with our detailed historical performance reports. Key Takeaways Click through to start exploring the rest of the 460 ASX Penny Stocks now. Seeking Other Investments? This technology could replace computers: discover the 26 stocks are working to make quantum computing a reality. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:BKI ASX:HLO and ASX:PHX. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
2 hours ago
- Yahoo
Investors in Corporate Travel Management (ASX:CTD) have seen strong returns of 102% over the past five years
When we invest, we're generally looking for stocks that outperform the market average. And while active stock picking involves risks (and requires diversification) it can also provide excess returns. For example, the Corporate Travel Management Limited (ASX:CTD) share price is up 88% in the last 5 years, clearly besting the market return of around 45% (ignoring dividends). However, more recent returns haven't been as impressive as that, with the stock returning just 21% in the last year, including dividends. So let's assess the underlying fundamentals over the last 5 years and see if they've moved in lock-step with shareholder returns. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time. During the last half decade, Corporate Travel Management became profitable. That would generally be considered a positive, so we'd hope to see the share price to rise. You can see how EPS has changed over time in the image below (click on the chart to see the exact values). We like that insiders have been buying shares in the last twelve months. Even so, future earnings will be far more important to whether current shareholders make money. It might be well worthwhile taking a look at our free report on Corporate Travel Management's earnings, revenue and cash flow. What About Dividends? When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. The TSR is a return calculation that accounts for the value of cash dividends (assuming that any dividend received was reinvested) and the calculated value of any discounted capital raisings and spin-offs. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. In the case of Corporate Travel Management, it has a TSR of 102% for the last 5 years. That exceeds its share price return that we previously mentioned. And there's no prize for guessing that the dividend payments largely explain the divergence! A Different Perspective It's nice to see that Corporate Travel Management shareholders have received a total shareholder return of 21% over the last year. And that does include the dividend. That gain is better than the annual TSR over five years, which is 15%. Therefore it seems like sentiment around the company has been positive lately. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. For instance, we've identified 1 warning sign for Corporate Travel Management that you should be aware of. There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Australian exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Investors Will Want Super Retail Group's (ASX:SUL) Growth In ROCE To Persist
There are a few key trends to look for if we want to identify the next multi-bagger. Typically, we'll want to notice a trend of growing return on capital employed (ROCE) and alongside that, an expanding base of capital employed. Ultimately, this demonstrates that it's a business that is reinvesting profits at increasing rates of return. So on that note, Super Retail Group (ASX:SUL) looks quite promising in regards to its trends of return on capital. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Return On Capital Employed (ROCE): What Is It? For those who don't know, ROCE is a measure of a company's yearly pre-tax profit (its return), relative to the capital employed in the business. To calculate this metric for Super Retail Group, this is the formula: Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities) 0.17 = AU$376m ÷ (AU$3.4b - AU$1.1b) (Based on the trailing twelve months to December 2024). Therefore, Super Retail Group has an ROCE of 17%. In absolute terms, that's a pretty normal return, and it's somewhat close to the Specialty Retail industry average of 16%. See our latest analysis for Super Retail Group Above you can see how the current ROCE for Super Retail Group compares to its prior returns on capital, but there's only so much you can tell from the past. If you're interested, you can view the analysts predictions in our free analyst report for Super Retail Group . The Trend Of ROCE Super Retail Group is displaying some positive trends. The numbers show that in the last five years, the returns generated on capital employed have grown considerably to 17%. The company is effectively making more money per dollar of capital used, and it's worth noting that the amount of capital has increased too, by 21%. So we're very much inspired by what we're seeing at Super Retail Group thanks to its ability to profitably reinvest capital. The Bottom Line All in all, it's terrific to see that Super Retail Group is reaping the rewards from prior investments and is growing its capital base. And with the stock having performed exceptionally well over the last five years, these patterns are being accounted for by investors. In light of that, we think it's worth looking further into this stock because if Super Retail Group can keep these trends up, it could have a bright future ahead. One more thing to note, we've identified 1 warning sign with Super Retail Group and understanding it should be part of your investment process. While Super Retail Group may not currently earn the highest returns, we've compiled a list of companies that currently earn more than 25% return on equity. Check out this free list here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
